Adverse Events with EMAs: Luspatercept
Dr Garcia-Manero offers insights on the adverse events profile associated with luspatercept in patients with lower-risk MDS.
EP: 1.Overview of Lower-Risk Myelodysplastic Syndromes (LR-MDS)
EP: 2.Standard-of-Care Treatment for Patients with LR-MDS
EP: 3.Erythroid Maturating Agents (EMAs) for Frontline or Second-Line Treatment of Anemia in LR-MDS
EP: 4.COMMANDS Trial: Study Design, Patient Population, and Results
EP: 5.Classification Changes Impacting the Treatment of LR-MDS
EP: 6.Dose Escalation of Luspatercept on Trial and Real-World Data
Now Viewing
EP: 7.Adverse Events with EMAs: Luspatercept
EP: 8.Current Approach for Treating Anemia in LR-MDS
EP: 9.Future Treatment for Anemia of LR-MDS
EP: 10.Clinical Pearls for Community Oncologist Treating LR-MDS
Video content above is prompted by the following:
- Please discuss the adverse events profile associated with luspatercept for any grade and ≥ grade 3 AEs.
- Which AEs are most concerning? Are hematologic or non-hematologic most common?
- How do you manage these events in your practice? Do the AEs have a significant impact on quality of life for patients?
Recent Videos
Related Content
Genetics and Ring Sideroblasts Impact ESA-Refractory Anemia in MDS
September 5th 2024Article
During a Case-Based Roundtable® event, Azra Raza, MD, discussed a patient case of myelodysplastic syndrome first treated with erythropoiesis-stimulating agent in the second article of a 2-part series.
Read More
Luspatercept in MDS Promotes Transfusion Independence and Anemia Response
August 21st 2024Article
During a Case-Based Roundtable® event, Azra Raza, MD, discussed a patient case and outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndrome in the first article of a 2-part series.
Read More
